Myriad Genetics to Join S&P SmallCap 600

NEW YORK, Feb. 10, 2017 /PRNewswire/ -- Myriad Genetics, Inc. (NASD: MYGN) will replace Inteliquent, Inc. (NASD: IQNT) in the S&P SmallCap 600 after the close on Tuesday, February 14. GTCR LLC has acquired Inteliquent in a deal expected to be completed today.

Myriad Genetics, a personalized medicine company, focuses on the development and marketing of predictive, personalized, and prognostic medicine tests. Headquartered in Salt Lake City, UT, the company will be added to the S&P SmallCap 600 GICS (Global Industry Classification Standard) Biotechnology Sub-Industry index.

Following is a summary of the changes:

For more information about S&P Dow Jones Indices, please visit www.spdji.com

ABOUT S&P DOW JONES INDICES

S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500^® and the Dow Jones Industrial Average^®. More assets are invested in products based on our indices than based on any other provider in the world. With over 1,000,000 indices and more than 120 years of experience constructing innovative and transparent solutions, S&P Dow Jones Indices defines the way investors measure and trade the markets.

S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

FOR MORE INFORMATION:

Luke Shane
North America Communications
New York, USA
(+1) 212 438 8184
luke.shane@spglobal.com

David Blitzer
Managing Director and Chairman of the Index Committee
New York, USA
(+1) 212 438 3907
david.blitzer@spglobal.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/myriad-genetics-to-join-sp-smallcap-600-300405837.html

SOURCE S&P Dow Jones Indices